End-stage renal disease patients up nearly 19%

Chauhan, Tara
March 2004
CMAJ: Canadian Medical Association Journal;3/30/2004, Vol. 170 Issue 7, p1087
Academic Journal
Focuses on the increasing number of patients being treated for end-stage renal disease (ESRD) in Canada. Percentage of increase in ESRD patients; Primary cause of ESRD; Presentation of a graph on ESRD patients aged 65 and over.


Related Articles

  • Aggressive therapy may reduce mortality for some patients with diabetes.  // Pharmacy Today;Mar2008, Vol. 14 Issue 3, p4 

    The article reports on the study which shows aggressive treatment for patients with diabetes may reduce mortality. The research indicates that treatment that targets multiple risk factors may reduce the risk of death in patients with type 2 diabetes and signs of kidney damage. Intensive therapy...

  • Baseline analysis of renal function in the Diabetes Control and Complications Trial. Molitch, Mark E.; Steffes, Michael W.; Cleary, Patricia A.; Nathan, David M. // Kidney International;Mar1993, Vol. 43 Issue 3, p668 

    To determine whether there are relationships between nephropathy, retinopathy and putative risk factors at points very early in the development of long-term complications of IDDM, we have analyzed baseline data pertinent to nephropathy in the 726 subjects in the primary prevention cohort and the...

  • Compliance with guidelines and predictors of mortality in hemodialysis. Learning from Serbia patients. Djukanović, Ljubica; Dimković, Nada; Marinković, Jelena; Andrić, Branislav; Bogdanović, Jasmina; Budošand, Ivana; Cvetičanine, Anica; Djordjev, Kosta; Djordjević, Verica; Djurić, Živka; Lilić, Branimir Havi ža; Jovanović, Nasta; Jelačić, Rosa; Knežević, Violeta; Kostićm, Svetislav; Lazarević, Tatjana; Ljubenovićm, Stanimir; Marić, Ivko; Marković, Rodoljub; Milenković, Srbol // Nefrologia;2015, Vol. 35 Issue 3, p287 

    Objectives: The aims of the study were to determine the percentage of patients on regular hemodialysis (HD) in Serbia failing to meet KDOQI guidelines targets and find out factors associated with the risk of time to death and the association between guidelines adherence and patient outcome....

  • Irbesartan cost saving in hypertensive patients with type 2DM.  // PharmacoEconomics & Outcomes News;11/6/2004, Issue 465, p7 

    Reports on the economic evaluation of Irbesartan in Diabetic Nephropathy Trial in Great Britain. Delay in the onset of end-stage renal disease; Cost savings associated with irbesartan treatment.

  • Ischemic Renal Disease in Kuwait. Sheikh, M.; Nampoory, M.R.N.; Sinan, T.; Al-Ali, A.; Johny, K.V. // Angiology;Jan/Feb2002, Vol. 53 Issue 1, p83 

    Examines the prevalence of ischemic renal disease (IRD) in Kuwait based on patients with advanced chronic renal failure (CRF). Age of the majority of patients with IRD; Level of serum creatinine in patients with IRD; Comparison between the incidence of diabetes mellitus in patients with IRD and...

  • Microalbuminuria Is Common in Japanese Type 2 Diabetic Patients. Yokoyama, Hiroki; Kawai, Koichi; Kobayashi, Masashi // Diabetes Care;Apr2007, Vol. 30 Issue 4, p989 

    The article reports on the results of a study regarding the prevalence of microalbuminuria in Japanese type 2 diabetic patients. It states that the prevalence of microalbuminuria and clinical nephropathy was 31.6. It has found that 40% of patients had no albumin-to-creatinine (ACR) measurements...

  • Metformin.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p145 

    The article presents a case study of a 77 year old woman with chronic kidney disease (CKD) and diabetes who is diagnosed with lactic acidosis caused by metformin therapy.

  • Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy. Forbes, Josephine M.; Thallas-Bonke, Vicki; Cooper, Mark E.; Thomas, Merlin C. // Current Pharmaceutical Design;Oct2004, Vol. 10 Issue 27, p3361 

    Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of...

  • Contrast nephropathy in patients with impaired renal function: High versus low osmolar media. Barrett, Brendan J.; Parfrey, Patrick S.; Vavasour, Hilary M.; McDonald, Jackie; Kent, Gloria; Hefferton, Donna; O'Dea, Frank; Stone, Eric; Reddy, Raj; McManamon, Patrick J. // Kidney International;May1992, Vol. 41 Issue 5, p1274 

    Prescription of low osmolar contrast to prevent nephrotoxicity in subjects with pre-existing renal impairment is costly and has not been clearly shown to be effective. We entered 249 subjects with a pre-contrast serum creatinine greater than 120 μmol/liter (1.35 mg/dl) having cardiac...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics